Mr. Budd (for himself and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions
To improve the inspections of drug establishments engaged in the manufacture, preparation, propagation, or processing of biosimilar biological products conducted by the Food and Drug Administration, and for other purposes.
Citations are generated automatically from bibliographic data as a convenience and may not be complete or accurate.
Chicago
U.S. Congress. Senate. Biosimilar Inspection Modernization Act of 2025. S. 3510. 119th
Cong., 1st
sess., Introduced in Senate December 16, 2025. https://www.govinfo.gov/app/details/BILLS-119s3510is.
APA
Congress, Senate (2025, December 16). Biosimilar Inspection Modernization Act of 2025 (S. 3510 (IS)). Retrieved from https://www.govinfo.gov/app/details/BILLS-119s3510is.
MLA
United States, Congress, Senate. Biosimilar Inspection Modernization Act of 2025. U.S. Government Publishing Office, https://www.govinfo.gov/app/details/BILLS-119s3510is. 119th Congress, S. 3510, Introduced in Senate 16 Dec. 2025.
Bluebook
S.3510 - 119th Congress (2025-2026): Biosimilar Inspection Modernization Act of 2025, S.3510, 119th Cong. (2025), https://www.govinfo.gov/app/details/BILLS-119s3510is.
